Clinical trials: Mammary Cancer
Early-stage Breast Cancer
Cardioprotective Effect of Acute Exercise in Breast Cancer Patients
Cardiotoxicity is one of the most significant adverse effects in breast cancer patients treated with anthracyclines (a type of chemotherapy), so we propose to determine whether acute training (i.e., 24h before each chemotherapy…
- Trial name
- CardioProtEx (NCT05467111)
- Testing
- Acute Exercise
- Where
- Spain
- Volunteers
- 40 people
- Sponsor
- Technical University of Madrid
Neoplasms, Breast
A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer
A study to compare the safety and efficacy of an aromatase inhibitor in combination with lapatinib, trastuzumab or both for the treatment of hormone receptor positive, HER2+ metastatic breast cancer (MBC).
- Trial name
- NCT01160211
- Testing
- Lapatinib, Trastuzumab, Aromatase Inhibitor
- Where
- 110 sites in United States, Argentina and 27 more
- Volunteers
- 369 people
- Sponsor
- Novartis Pharmaceuticals
Metastatic Breast Cancer, Unresectable Breast Cancer
A Study of Letrozole, Palbociclib, and Onapristone ER in People With Metastatic Breast Cancer
The researchers are doing this study to find out whether the study drug onapristone ER, combined with the standard treatment for your cancer (letrozole and palbociclib), is a safe treatment for people who have metastatic or…
- Trial name
- NCT04872608
- Testing
- Letrozole, Palbociclib, Onapristone ER
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Breast Cancer Patients
Catheter Tip Position and Contrast Distribution Following Paravertebral Catheter Insertion: a CT Study
This retrospective study aims to assess the impact of paravertebral catheter insertion depth on the final anatomical position of the catheter tip.
- Trial name
- NCT07064317
- Where
- Belgium
- Volunteers
- 31 people
- Sponsor
- Ziekenhuis Oost-Limburg
Breast Cancer
Neoadjuvant SBRT Followed by Nab-Paclitaxel Combined With Toripalimab in HR+/HER2- Breast Cancer
The goal of this clinical trial is to evaluate the efficacy and safety of neoadjuvant stereotactic body radiotherapy (SBRT) followed by nab-paclitaxel combined with toripalimab in patients with previously untreated…
- Trial name
- NCT06914440
- Testing
- Stereotactic Body Radiation Therapy (SBRT), Toripalimab, Neoadjuvant Chemotherapy
- Where
- 2 sites in China
- Volunteers
- 27 people
- Sponsor
- Xijing Hospital
Musculoskeletal Syndrome
A Feasibility Study of Topical Cannabinoids for Treatment of Aromatase Inhibitor-Associated Musculoskeletal Syndrome (AIMSS) in Adults With Hormone Receptor-Positive Breast Cancer (CanAroma)
Aromatase inhibitors (AIs) are commonly used for post-menopausal women with hormone-positive breast cancer. Compared to tamoxifen, AIs improve breast cancer recurrence rates and lower 10-year breast cancer mortality.
- Trial name
- NCT05935891
- Testing
- CBD-dominant, THC dominant
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Minnesota
Breast Cancer, Neoplasm Metastasis
Capecitabine Associated With Weekly Paclitaxel in Metastatic Breast Cancer.
Tolerance and efficacy of administration of capecitabine 5 out of 7 days associated with weekly paclitaxel compared to the recommended treatment plan of weekly paclitaxel - capecitabine, in patients with metastatic breast cancer.
- Trial name
- NCT00270491
- Testing
- Paclitaxel, Capecitabine
- Where
- France
- Volunteers
- 130 people
- Sponsor
- ARCAGY/ GINECO GROUP
Breast Cancer Lymphedema
Warm Acupuncture for Breast Cancer Related Lymphedema
The purpose of this study is to clarify whether local-distal point association is more effective than local point association by warm acupuncture in the management of breast cancer related lymphedema.
- Trial name
- NCT03373474
- Testing
- local distribution points association, local-distal points association
- Where
- China
- Volunteers
- 108 people
- Sponsor
- Tianjin University of Traditional Chinese Medicine
Breast Neoplasms
Randomized Phase II Trial of Anastrozole Plus Metronomic Tegafur-uracil as Neo-adjuvant Therapy in Postmenopausal Breast Cancer
The Aim of this study is to validate a treatment of anastrozole in combination with tegafur-uracil as pre-operative therapy for postmenopausal primary breast cancer.
- Trial name
- Neo-ACET BC (NCT01262274)
- Testing
- Anastrozole, Anastrozole plus tegafur-uracil
- Where
- Japan
- Volunteers
- 57 people
- Sponsor
- Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
Progression-free Survival
Study of Faslodex With or Without Concomitant Arimidex Versus Exemestane Following Progression on Non-steroidal Aromatase Inhibitors (NSAI)
A partially-blind, randomised, multicentre phase III trial of Faslodex plus concomitant Arimidex versus Faslodex plus Arimidex-Placebo versus exemestane in postmenopausal locally advanced / metastatic breast cancer patients who…
- Trial name
- NCT00944918
- Testing
- fulvestrant, anastrozole, exemestane
- Where
- 2 sites in South Korea
- Volunteers
- 25 people
- Sponsor
- AstraZeneca
Breast Cancer
Trial of Perioperative Endocrine Therapy - Individualising Care
To determine whether perioperative endocrine therapy with an aromatase inhibitor (AI) followed by standard adjuvant therapy improves outcome compared with standard adjuvant therapy alone in postmenopausal women with hormone…
- Trial name
- POETIC (NCT02338310)
- Testing
- Aromatase Inhibitors
- Where
- 128 sites in United Kingdom
- Volunteers
- 4,486 people
- Sponsor
- Institute of Cancer Research, United Kingdom
Triple-Negative Breast Cancer
Precise Treatment for BLIS Subtype of TNBC in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer
The study is being conducted to evaluate VEGFR BP102 with nab-paclitaxe or treatment of physician's choice (TPC) versus nab-paclitaxe or TPC in patients for basal-like immune suppressed (BLIS) subtype of triple-negative breast…
- Trial name
- BCTOP-T-M01 (NCT05806060)
- Testing
- VEGFR and TPC, TPC
- Where
- China
- Volunteers
- 134 people
- Sponsor
- Fudan University
Breast Ductal Carcinoma In Situ
A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ
This phase Ib trial studies the side effects and best dose of a vaccine called H2NVAC before surgery in treating patients with HER2 expressing ductal carcinoma in situ.
- Trial name
- NCT04144023
- Testing
- Granulocyte-Macrophage Colony-Stimulating Factor, Multi-epitope HER2 Peptide Vaccine H2NVAC, Therapeutic Conventional Surgery
- Where
- 2 sites in United States
- Volunteers
- 43 people
- Sponsor
- Mayo Clinic
Melanoma, Meningioma
T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer
Background: The National Cancer Institute (NCI) Surgery Branch has developed an experimental therapy for treating patients with cancer that involves taking white blood cells from the patient, growing them in the laboratory in…
- Conditions
- Melanoma, Meningioma, Breast Cancer, Non-Small Cell Lung Cancer
- Trial name
- NCT01967823
- Testing
- Anti-NY ESO-1 mTCR PBL, Cyclophosphamide, Fludarabine
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer, Triple Negative Breast Neoplasms
Evaluate the Clinical Benefit of a Post-operative Treatment Associating Radiotherapy + Nivolumab + Ipilimumab Versus Radiotherapy + Capecitabine for Triple Negative Breast Cancer Patients With Residual Disease
To evaluate the clinical benefit of a post-operative adjuvant therapy combining radiotherapy + Nivolumab + Ipilimumab versus radiotherapy + Capecitabine in Triple Negative Breast Cancer (TNBC) patients with residual disease after…
- Trial name
- BreastImmune03 (NCT03818685)
- Testing
- Nivolumab, Ipilimumab, Capecitabine
- Where
- 17 sites in France
- Volunteers
- 95 people
- Sponsor
- Centre Leon Berard
Breast Cancer, Ductal Carcinoma In Situ
Breast Tumour Size Measurement by Field Cycling Imaging
The goal of this study is to test if a new type of MRI scanner, called Field-Cycling Imaging (FCI), can accurately estimate tumour size in patients with a type of breast cancer called ductal carcinoma in situ (DCIS).
- Trial name
- BREVIA (NCT07492043)
- Testing
- Field-Cycling Imaging research scan, 3T MRI research scan
- Where
- United Kingdom
- Volunteers
- 12 people
- Sponsor
- University of Aberdeen
Breast Cancer, Breast Neoplasm
Primary Chemotherapy With Docetaxel-Capecitabine and Doxorubicin-Cyclophosphamide in Breast Cancer
This study will assess the usefulness of a technique called complementary deoxyribonucleic acid (cDNA) microarray-an examination of a wide array of genes to identify disease-associated patterns-for measuring tumor response to…
- Trial name
- NCT00005908
- Testing
- Docetaxel - Dose A, Anastrozole, cyclophosphamide
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Cancer Related Fatigue
Trial of Exercise to Reduce Cancer Related Fatigue in Breast Cancer
Like other cancer treatments, radiation therapy can make people feel fatigued, or tired. The investigators think that moderate exercise, done 15 minutes at a time, can reduce the fatigue.
- Trial name
- NCT02846389
- Testing
- Moderate Exercise
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Hackensack Meridian Health
Breast Carcinoma
Comparison of Synthetic Mammography Versus Full-Field Digital Mammography in Image Interpretation and Performance Metrics
This study compares synthetic mammography to full-field digital mammography in image interpretation and performance metrics. Digital breast tomosynthesis (DBT) has previously been found to be superior in performance to standard…
- Trial name
- NCT05056818
- Testing
- Electronic Health Record Review
- Where
- United States
- Volunteers
- 750 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer Early Stage Breast Cancer (Stage 1-3)
Evaluation of HER2DX Assay on Treatment Decisions in Patients With Early Stage HER2+ Breast Cancer: the HER2BREASTDX
To prospectively evaluate the impact of HER2DX on the decision-making processes of the treating physicians and especially among the routine multidisciplinary tumour board, in defining type and setting of systemic therapy…
- Trial name
- HER2BREASTDX (NCT06723990)
- Testing
- Neoadjuvant standard treatment for HER2+, Adjuvant standard treatment for HER2+
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- European Institute of Oncology
The first 5,000 results can be paged through. Add a filter or change the sort order to reach the rest.